Abbott Laboratories (NYSE:ABT) Announces $0.63 Quarterly Dividend

Abbott Laboratories (NYSE:ABT) announced a quarterly dividend on Thursday, September 17th. Investors of record on Thursday, October 15th will be paid a dividend of 0.63 per share by the healthcare product maker on Monday, November 16th. This represents a c) dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th.

Abbott Laboratories has increased its dividend by an average of 0.1%annually over the last three years and has raised its dividend annually for the last 54 consecutive years. Abbott Laboratories has a payout ratio of 44.4% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Abbott Laboratories to earn $6.08 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 41.4%.

Abbott Laboratories Trading Down 0.2%

NYSE ABT opened at $102.20 on Friday. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The stock’s 50 day moving average price is $106.18 and its two-hundred day moving average price is $99.38. The stock has a market capitalization of $176.84 billion, a price-to-earnings ratio of 33.07, a PEG ratio of 1.90 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same period last year, the company earned $1.26 earnings per share. The firm’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Institutional Trading of Abbott Laboratories

Hedge funds and other institutional investors have recently modified their holdings of the stock. J. Stern & Co. LLP increased its position in Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after buying an additional 39,005,451 shares during the period. Norges Bank bought a new position in shares of Abbott Laboratories in the fourth quarter worth $2,938,892,000. Bank of America Corp DE acquired a new position in Abbott Laboratories in the second quarter valued at about $1,603,607,000. Legal & General Group Plc bought a new stake in Abbott Laboratories during the second quarter worth about $1,082,524,000. Finally, Flossbach Von Storch SE acquired a new stake in Abbott Laboratories during the second quarter worth about $902,938,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.